Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban outcomes and laboratory monitoring in short bowel syndrome patients on long-term parenteral nutrition
NL-OMON60348Phase 4Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of rivaroxaban in thromboembolism and Atrial fibrillation (AFib), sponsored by Amsterdam University Medical Center. Primary endpoints: Clinical outcomes after one year, Venous thromboembolism and 4 more. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
rivaroxaban
03
Conditions
thromboembolismAtrial fibrillation (AFib)
Beyond the preview
Go deeper on NL-OMON60348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60348.